114 related articles for article (PubMed ID: 36366338)
1. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M; Yakushijin K; Funakoshi Y; Ohji G; Ichikawa H; Sakai H; Hojo W; Saeki M; Hirakawa Y; Matsumoto S; Sakai R; Nagao S; Kitao A; Miyata Y; Koyama T; Saito Y; Kawamoto S; Yamamoto K; Ito M; Murayama T; Matsuoka H; Minami H
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366338
[TBL] [Abstract][Full Text] [Related]
2. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
Watanabe M; Yakushijin K; Funakoshi Y; Ohji G; Hojo W; Sakai H; Saeki M; Hirakawa Y; Matsumoto S; Sakai R; Nagao S; Kitao A; Miyata Y; Koyama T; Saito Y; Kawamoto S; Ito M; Murayama T; Matsuoka H; Minami H
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214617
[TBL] [Abstract][Full Text] [Related]
3. Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Henig I; Isenberg J; Yehudai-Ofir D; Leiba R; Ringelstein-Harlev S; Ram R; Avni B; Amit O; Grisariu S; Azoulay T; Slouzkey I; Zuckerman T
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112688
[TBL] [Abstract][Full Text] [Related]
4. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
J Infect Chemother; 2023 Mar; 29(3):274-280. PubMed ID: 36442827
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
6. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
Nagafuji K
Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
[TBL] [Abstract][Full Text] [Related]
7. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial.
Matkowska-Kocjan A; Owoc-Lempach J; Ludwikowska K; Szenborn F; Moskwa N; Kurek K; Kałwak K; Szenborn L; Ussowicz M
Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680039
[TBL] [Abstract][Full Text] [Related]
10. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
14. Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts.
Takagi E; Terakura S; Fujigaki H; Okamoto A; Miyao K; Sawa M; Morishita T; Goto T; Ozawa Y; Nishida T; Fukushima N; Ozeki K; Hanajiri R; Saito K; Murata M; Tomita A; Kiyoi H
Int J Hematol; 2023 Oct; 118(4):462-471. PubMed ID: 37561340
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
16. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
17. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
Leclerc M; Redjoul R; Le Bouter A; Beckerich F; Robin C; Parinet V; Pautas C; Menouche D; Bouledroua S; Roy L; Cabanne L; Nait-Sidenas Y; Fourati S; Maury S
J Hematol Oncol; 2022 Mar; 15(1):27. PubMed ID: 35303906
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
19. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
Front Oncol; 2021; 11():737300. PubMed ID: 34552880
[TBL] [Abstract][Full Text] [Related]
20. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]